...ascending-doses of TS01 with or without a C1 esterase inhibitor in 50-70 healthy male volunteers. Thrombolytic Science International LLC...

...from Schering AG , now part of Bayer. Victor Gurewich, cofounder and scientific director of Thrombolytic Science International LLC...
...Harvard Medical School and director of Beth Israel Deaconess Medical Center 's Vascular Research Laboratory. Thrombolytic Science's...
...Inc. , Toronto, Ontario, Canada Paion AG (Xetra:PA8), Aachen, Germany Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Thrombolytic Science International LLC...

...trials in the '80s and '90s, according to Alexis Wallace, president, CEO and co-founder of Thrombolytic Science...
...product also is more stable than tPA because M5 is inert until reaching a clot. Thrombolytic Science...
...South San Francisco, Calif. Harvard Medical School, Cambridge, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Thrombolytic Science International LLC...

...In 2010, the company raised $2.5 million in seed funding from the same angel investor. Thrombolytic Science's...